¼¼°èÀÇ ½Å°æ Àç»ý ¿ä¹ý ½ÃÀå
Neuroregeneration Therapy
»óǰÄÚµå : 1731850
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å°æ Àç»ý ¿ä¹ý ¼¼°è ½ÃÀåÀº 2030³â±îÁö 472¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 378¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å°æ Àç»ý ¿ä¹ý ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 3.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 472¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ N-methyl-D-aspartate Receptor Antagonists´Â CAGR 4.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 179¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Äݸ°¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 103¾ï ´Þ·¯, Áß±¹Àº CAGR 7.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æ Àç»ý ¿ä¹ý ½ÃÀåÀº 2024³â¿¡ 103¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 95¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.0%·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.5%¿Í 2.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.2%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ½Å°æ Àç»ý ¿ä¹ý ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

½Å°æ Àç»ý ¿ä¹ýÀÌ CNS ¹× PNS ¼Õ»ó Ä¡·á¿¡¼­ Àü ¼¼°èÀûÀ¸·Î ¸ð¸àÅÒÀ» ¾ò°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

½Å°æÀç»ýÄ¡·á´Â ½Å°æ°úÇаú Àç»ýÀÇ·áÀÇ ÃÖÀü¹æ ¿µ¿ªÀ¸·Î ºÎ»óÇÏ¿© ÁßÃ߽Űæ°è¿Í ¸»ÃʽŰæ°è ¼Õ»óÀ¸·Î °íÅë¹Þ´Â ȯÀڵ鿡°Ô Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ±âÁ¸¿¡ µ¹ÀÌų ¼ö ¾ø´Â °ÍÀ¸·Î ¿©°ÜÁ³´ø ¿Ü»ó, ³úÁ¹Áß, ½Å°æÅðÇ༺ Áúȯ, Å»¼öÃÊ·Î ÀÎÇÑ ½Å°æ ¼Õ»óÀº ÇöÀç Ãà»è Àç»ý, ½Ã³À½º Àç°Ç, Àç¼öÃÊÈ­, ±â´É ȸº¹À» ÃËÁøÇÏ´Â ÁßÀçÀû Ä¡·áÀÇ ´ë»óÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´ëÁõ¿ä¹ý¿¡¼­ ½ÇÁ¦ ½Å°æÁ¶Á÷ º¹±¸·ÎÀÇ ÆÐ·¯´ÙÀÓ ÀüȯÀº ½Å°æÇÐÀû ÀçȰ¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ½Å°æÀç»ýÀ» ¹Ì·¡ ½Å°æÄ¡·áÇÐÀÇ Ãʼ®À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½Å°æ Àç»ý Ä¡·á ¼ö¿ä¸¦ ÁÖµµÇÏ´Â °ÍÀº Àü ¼¼°èÀûÀ¸·Î ô¼ö ¼Õ»ó, ´Ù¹ß¼º °æÈ­Áõ, ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, ¿Ü»ó¼º ³ú¼Õ»óÀÇ ¹ß»ý·ü Áõ°¡ÀÔ´Ï´Ù. Àα¸ °í·ÉÈ­, ±³Åë »ç°í ¹× ½ºÆ÷Ã÷ °ü·Ã ¿Ü»ó Áõ°¡·Î ÀÎÇØ ¼è¾à¼º ½Å°æ Àå¾Ö¸¦ ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ ¼ö´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ Ä¡·á¹ýÀº ȸº¹ °¡´É¼ºÀÌ Á¦ÇÑÀûÀ̸ç, Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ¿Í ´Þ¸® ½Å°æ Àç»ý Ä¡·á´Â ÀÒ¾î¹ö¸° ±â´ÉÀ» ȸº¹½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ¿ÏÈ­Àû Ä¡·á Àü·«ÀÌ ¾Æ´Ñ Ä¡·áÀû Â÷¼¼´ë Ä¡·á Àü·«À» âÃâÇϰí ÀÖ½À´Ï´Ù.

Áٱ⼼Æ÷, ¼ºÀåÀÎÀÚ, À¯ÀüÀÚ Ä¡·á µî »õ·Î¿î Ä¡·á¹ýÀº ½Å°æÀç»ýÀ» ¾î¶»°Ô º¯È­½Ãų±î?

½Å°æ Àç»ý Ä¡·áÀÇ ±â¼úÀû ÇÙ½ÉÀº ÃÖ÷´Ü »ý¹°ÇÐÀû Á¦Á¦¿Í Àΰø ¼¼Æ÷ ½Ã½ºÅÛÀ» Áß½ÉÀ¸·Î Àü°³µÇ°í ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á, ƯÈ÷ Áß°£¿±Áٱ⼼Æ÷(MSC), À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC), ½Å°æÀü±¸¼¼Æ÷´Â ÀÓ»ó °³¹ß ÁßÀÎ ÃÖ÷´Ü Á¢±Ù¹ý Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ¼¼Æ÷µéÀº ½Å°æ ¿µ¾ç ÀÎÀÚ¸¦ ºÐºñÇϰí, ¿°ÁõÀ» Á¶ÀýÇϸç, ¼Õ»óµÈ ½Å°æÁ¶Á÷À» º¹±¸ÇÏ´Â ´º·± À¯»ç ¼¼Æ÷·Î ºÐÈ­ÇÕ´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ ô¼ö ¼Õ»ó, ³úÁ¹Áß È¸º¹, ALS, ´Ù¹ß¼º °æÈ­Áõ µî¿¡ ´ëÇÑ »ç¿ëÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, Ãʱ⿡´Â À¯¸ÁÇÑ °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

³úÀ¯·¡ ½Å°æ¿µ¾çÀÎÀÚ(BDNF), ½Å°æ±³¼¼Æ÷ÁÖ À¯·¡ ½Å°æ¿µ¾çÀÎÀÚ(GDNF), ¸ðü ½Å°æ¿µ¾çÀÎÀÚ(CNTF)¸¦ Æ÷ÇÔÇÑ ¼ºÀåÀÎÀÚ Ä¡·á´Â ½Å°æ¼¼Æ÷ÀÇ »ýÁ¸°ú °¡¼Ò¼ºÀ» ÃËÁøÇϱâ À§ÇØ ¹ÙÀÌ·¯½º º¤ÅÍ, »ýüÀç·á ¶Ç´Â Á÷Á¢ ÁÖÀÔÀ¸·Î Åõ¿©µÇ°í ÀÖ½À´Ï´Ù. ½Å°æ ¿°Áõ, ¹Ì¿¤¸° º¹±¸, ½Ã³À½º ±â´É Àå¾Ö¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â À¯ÀüÀÚ Ä¡·á´Â ƯÈ÷ À¯Àü¼º ½Å°æ ÅðÇ༺ Áúȯ¿¡¼­ °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. »ýüÀç·á ½ºÄ³Æúµå, ÇÏÀ̵å·Î°Ö ¸ÅÆ®¸¯½º, ½Å°æ ÀÎÅÍÆäÀ̽ºÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ Àç»ýÁ¦¸¦ ±¹¼ÒÀûÀ¸·Î Áö¼ÓÀûÀ¸·Î Åõ¿©ÇÏ´Â °Íµµ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´Ü¼øÇÑ Áõ»ó ¾ïÁ¦º¸´Ù´Â ½Å°æ ȸº¹°ú ȸ·Î ÀçÅëÇÕ¿¡ ÁßÁ¡À» µÎ¾î Ä¡·á¿¡ ´ëÇÑ ±â´ë¸¦ ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù.

½Å°æ Àç»ý ½ÃÀå »óȲÀ» Çü¼ºÇÏ´Â ÀÓ»ó Àû¿ë ¹× ȯÀÚ Áý´ÜÀº?

½Å°æÀç»ýÄ¡·á´Â ô¼ö¼Õ»ó, ¿Ü»ó¼º ³ú¼Õ»ó(TBI), ¸»ÃʽŰæ¼Õ»ó, ÇãÇ÷¼º ³úÁ¹Áß, ´Ù¹ß¼º °æÈ­Áõ, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´°ú °°Àº ½Å°æÅðÇ༺ Áúȯ µî ´Ù¾çÇÑ ÀÓ»ó ÀÀ¿ë ºÐ¾ß¿¡¼­ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¸¸¼º ½Å°æ ¼Õ»ó, ƯÈ÷ ºÎºÐÀû ±â´É ÀÜÁ¸ ¹× Ãʱ⠴ܰèÀÇ ÅðÇ༺ ½Å°æ ¼Õ»ó ȯÀÚ´Â ÇöÀç Àç»ý Ä¡·áÀÇ °¡Àå ÁÁÀº Èĺ¸ÀÔ´Ï´Ù. ¼Ò¾Æ ½Å°æ ºÐ¾ß, ƯÈ÷ ³ú¼º¸¶ºñ ¹× ¼±Ãµ¼º ½Å°æ°ü °á¼ÕÁõµµ ÇâÈÄ Ä¡·á Çõ½ÅÀÇ ´ë»óÀÔ´Ï´Ù.

ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µî ½Å°æ¿Ü»ó, ³úÁ¹Áß, ³ëÈ­¿¡ µû¸¥ ½Å°æº¯¼º ¹ß»ý·üÀÌ ³ôÀº Áö¿ªÀÌ ÀÓ»ó½ÃÇè Ȱµ¿°ú ½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ±ÔÁ¦ ¹ßÀü°ú Áٱ⼼Æ÷ ÀÓ»ó ÀÎÇÁ¶ó ±¸Ãà Ãø¸é¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, ÀϺ»°ú Çѱ¹Àº À¯¸®ÇÑ ±ÔÁ¦ ü°è ¾Æ·¡ Àç»ýÀÇ·á ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ÀÇ ½ÅÈï ½ÃÀåµéÀº Àç»ýÀÇ·á ÀÎÇÁ¶ó ±¸Ãà°ú ±¹Á¦ ÀÓ»ó½ÃÇè Âü¿©¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ½ÇÇèÀû Àç»ýÄ¡·á¿¡ ´ëÇÑ Æø³ÐÀº Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ȯÀÚµéÀÇ ÁöÁö¿Í ÀÓ»ó½ÃÇè Âü¿©¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀåÀÇ Àúº¯ÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù.

½Å°æÀç»ýÄ¡·á ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå°ú Çõ½ÅÀÇ ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

½Å°æÀç»ýÄ¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº Áٱ⼼Æ÷»ý¹°ÇÐ, »ýüÀç·á°úÇÐ, ºÐÀڽŰæ»ý¹°ÇÐ, Á¤¹ÐÀ¯ÀüÀÚÆíÁýÀÇ À¶ÇÕÀÔ´Ï´Ù. ½Å°æ°èÀÇ °¡¼Ò¼º°ú ³»Àμº ȸº¹ ¸ÞÄ¿´ÏÁòÀ» ÀÚ±ØÇÏ´Â ´É·ÂÀÌ ÀνĵǸ鼭 ½Å°æ ¼Õ»ó¿¡ ´ëÇÑ ÀÓ»óÀû Á¢±Ù¹ýÀÌ º¯È­Çϰí ÀÖ½À´Ï´Ù. Àç»ý ½Å°æÄ¡·áÁ¦ÀÇ °³¹ß ¹× »ó¿ëÈ­¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ Ã·´ÜÄ¡·áÁ¦(ATMPs)¿¡ ´ëÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ½Å°æ Àç»ý ¿¬±¸¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ÅõÀÚ°¡ È®´ëµÇ°í ÀÖÀ¸¸ç, ´ÙÇÐÁ¦°£ °øµ¿¿¬±¸°¡ Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó °ËÁõ, È®Àå °¡´ÉÇÑ Á¦Á¶, À±¸®Àû Á¶´Þ, Àå±âÀûÀÎ ¾ÈÀü¼º ¸ð´ÏÅ͸µÀº ¿©ÀüÈ÷ Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù. ±×·¯³ª Ãʱ⠴ܰèÀÇ ½ÃÇè¿¡¼­ ¾òÀº µ¥ÀÌÅͰ¡ ¼º¼÷Çϰí Àü´Þ ±â¼úÀÌ ´õ¿í Á¤±³ÇØÁü¿¡ µû¶ó, ½Å°æ Àç»ý Á¦Ç°ÀÇ ¼ö°¡ Áõ°¡ÇÏ°í ½ÃÀå ½ÂÀο¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µðÁöÅÐ ½Å°æ ÀçȰ µµ±¸, Âø¿ëÇü ½Å°æ Àڱرâ, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ÅëÇÕÀÌ ÁøÀüµÇ¸é Ä¡·á ¼øÀÀµµ¿Í °á°ú ÃßÀûÀÌ ´õ¿í °­È­µÉ °ÍÀÔ´Ï´Ù. ½Å°æ Àç»ýÀÌ ½Å°æ Ä¡·áÀÇ Áß¿äÇÑ ÃàÀ¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÇ ±â´É ȸº¹°ú »îÀÇ Áú Çâ»ó¿¡ ȹ±âÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÎ¹®

¾àÁ¦ À¯Çü(N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, ±âŸ ¾àÁ¦ À¯Çü), ÀûÀÀÁõ À¯Çü(ÆÄŲ½¼º´ ÀûÀÀÁõ, ¾ËÃ÷ÇÏÀ̸Ӻ´ ÀûÀÀÁõ, ´Ù¹ß¼º °æÈ­Áõ ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ), Åõ¿© °æ·Î(°æ±¸ °æ·Î, ºñ°æ±¸ °æ·Î, °æÇÇ °æ·Î), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¾à±¹ ÃÖÁ¾»ç¿ëÀÚ, ¼Ò¸Å ¾à±¹ ÃÖÁ¾»ç¿ëÀÚ, ¿Â¶óÀÎ ¾à±¹ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ ÇÕ°è 42°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

¹«·á ¾÷µ¥ÀÌÆ® °¢±¹ÀÇ ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ, 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» °í°´´Ôµé²² Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neuroregeneration Therapy Market to Reach US$47.2 Billion by 2030

The global market for Neuroregeneration Therapy estimated at US$37.8 Billion in the year 2024, is expected to reach US$47.2 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. N-methyl-D-aspartate Receptor Antagonists, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.9 Billion by the end of the analysis period. Growth in the Cholinesterase Inhibitors segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.3 Billion While China is Forecast to Grow at 7.0% CAGR

The Neuroregeneration Therapy market in the U.S. is estimated at US$10.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.5 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Neuroregeneration Therapy Market - Key Trends & Drivers Summarized

Why Is Neuroregeneration Therapy Gaining Global Momentum in the Treatment of CNS and PNS Injuries?

Neuroregeneration therapy is emerging as a frontier area in neuroscience and regenerative medicine, offering hope for patients suffering from central and peripheral nervous system damage. Traditionally considered irreversible, neural injuries caused by trauma, stroke, neurodegenerative diseases, or demyelination are now being targeted with interventions that promote axonal regrowth, synaptic reformation, remyelination, and functional recovery. This paradigm shift from symptomatic management to actual nerve tissue repair is revolutionizing neurological rehabilitation and positioning neuroregeneration as a cornerstone of future neurotherapeutics.

The demand for neuroregeneration therapy is driven by the increasing global incidence of spinal cord injuries, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and traumatic brain injuries. With an aging population and rising road traffic accidents and sports-related traumas, the number of individuals suffering from debilitating neurological impairments continues to rise. Traditional therapies offer limited recovery potential and focus largely on slowing disease progression. In contrast, neuroregeneration therapies aim to restore lost function, giving rise to a new generation of curative, rather than palliative, treatment strategies.

How Are Emerging Modalities Like Stem Cells, Growth Factors, and Gene Therapies Transforming Neuroregeneration?

The technological core of neuroregeneration therapy revolves around cutting-edge biologics and engineered cell systems. Stem cell therapy-particularly mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural progenitor cells-is one of the most advanced approaches under clinical development. These cells secrete neurotrophic factors, modulate inflammation, and differentiate into neuron-like cells that aid in repairing damaged neural tissue. Clinical trials are exploring their use in spinal cord injuries, stroke recovery, ALS, and multiple sclerosis with promising early results.

Growth factor therapies-including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF)-are being delivered through viral vectors, biomaterials, or direct infusion to promote neuronal survival and plasticity. Gene therapies targeting neuroinflammation, myelin repair, or synaptic dysfunction are showing potential, especially in hereditary neurodegenerative diseases. Advances in biomaterial scaffolds, hydrogel matrices, and neural interfaces are also enabling localized, sustained delivery of these regenerative agents. These innovations are redefining therapeutic expectations, emphasizing neural restoration and circuit reintegration over mere symptom suppression.

Which Clinical Applications and Patient Populations Are Shaping the Neuroregeneration Market Landscape?

Neuroregeneration therapy is being investigated across a wide range of clinical applications, including spinal cord injuries, traumatic brain injuries (TBIs), peripheral nerve injuries, ischemic stroke, multiple sclerosis, and neurodegenerative diseases such as ALS and Parkinson’s. Patients with chronic neural damage-especially those with partial residual function or early-stage degeneration-are currently the best candidates for regenerative intervention. The pediatric neurology segment, particularly in cerebral palsy and congenital neural tube defects, is also a target for future therapeutic innovation.

Regions with high incidence of neurotrauma, stroke, and aging-related neurodegeneration-such as North America, Europe, and Asia-Pacific-are driving clinical trial activity and market demand. The U.S. leads in terms of regulatory progress and stem cell clinical infrastructure, while Japan and South Korea are advancing regenerative trials under favorable regulatory regimes. Emerging markets in Latin America and the Middle East are investing in rehabilitation infrastructure and international trial participation, enabling wider access to experimental regenerative therapies. Increasing patient advocacy and awareness of clinical trial participation are further broadening the market’s reach.

What Is Driving Long-Term Growth and Innovation in the Neuroregeneration Therapy Market?

The growth in the neuroregeneration therapy market is driven by the convergence of stem cell biology, biomaterials science, molecular neurobiology, and precision gene editing. The recognition of the nervous system’s plasticity and the ability to stimulate endogenous repair mechanisms is shifting the clinical approach to neural injuries. Regulatory frameworks for advanced therapy medicinal products (ATMPs) are being refined to accelerate the development and commercialization of regenerative neurotherapies. Public and private investment in neurorestorative research is expanding, with cross-disciplinary collaboration fueling innovation.

Clinical validation, scalable manufacturing, ethical sourcing, and long-term safety monitoring remain critical challenges. However, as data from early-phase trials mature, and as delivery technologies become more refined, a growing number of neuroregeneration products are expected to reach market approval. The increasing integration of digital neurorehabilitation tools, wearable neurostimulation devices, and remote patient monitoring systems will further enhance treatment adherence and outcome tracking. As neuroregeneration becomes a key pillar of neurotherapeutics, it will play a transformative role in improving functional recovery and quality of life for millions worldwide.

SCOPE OF STUDY:

The report analyzes the Neuroregeneration Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types); Indication Type (Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication, Other Indications); Administration Route (Oral Route, Parenteral Route, Transdermal Route); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â